Build Sequence: Formation to First-in-Human

A biopharmaceutical company is not launched. It is staged. Every other business on this site opens a door, serves a customer, and books revenue in month one. You will not book product revenue for the better part of a decade — therapeutics typically run seven to ten years from discovery to market — and your business plan has to be honest about that from the first paragraph, because the reader already knows it.

That single fact reshapes the document. A restaurant plan is a P&L story. A biopharmaceutical plan is a capital-ladder story: here is the next value inflection, here is what it costs to reach it, here is what the asset is worth once we get there, and here is who pays. Investors are not underwriting your year-five margin. They are underwriting your ability to hit the next gate before the money runs out.

The sequence below is the spine most plans should follow. Timings assume a virtual company built around a single lead biologic, using contract partners rather than owned facilities. Treat the months as planning anchors, not promises — programmes slip, and a plan that pretends otherwise reads as inexperience.

Months 0–6 — Formation, IP and the honest asset assessment

• Corporate structure and licence-in. If the science came out of a university, the exclusive licence terms are part of your cap table. Investors read the licence before they read the plan.
• Patent position. A PCT filing plus national-phase entry and a freedom-to-operate opinion typically runs $90K–$350K (£70K–£275K). This is the cheapest money you will ever spend and the most damaging to defer.
• Target product profile (TPP). One page describing the label you intend to earn: indication, population, route, dosing, comparator, and the efficacy bar that makes the drug commercially real rather than academically interesting.
• Kill criteria. Name, in writing, the result that stops the programme. Founders who cannot answer this are telling investors they will spend the round proving themselves right.

Months 6–18 — Cell line, process and the CMC foundation

• Cell-line development. Clone selection, stability testing, and a research cell bank. Locked in early, because changing the cell line after tox work restarts comparability.
• Upstream and downstream process development. Titre, yield, aggregation, host-cell protein clearance. The economics of your future COGS are decided here, not in the commercial plan.
• Analytical method development. Identity, purity, potency. Regulators will not accept a clinical result generated by an unqualified assay.
• CDMO selection and tech transfer readiness. See the manufacturing section below — this is the decision with the largest effect on your burn.

Months 12–24 — IND-enabling work

• GLP toxicology in two species where the biology requires it, typically $250K–$1.6M (£195K–£1.26M) and frequently the longest pole in the tent.
• GMP engineering run, then the clinical batch. The material is often more expensive than the trial that consumes it. Plans that budget the clinic and forget the drug substance are the most common failure we see.
• Pre-IND meeting with the FDA (or MHRA scientific advice in the UK). A written response to a well-framed pre-IND question is worth more than another six months of internal debate.
• Quality system stand-up. An eQMS, SOPs, GxP training and a named QP if you are operating under a UK MIA(IMP).

Months 24–30 — Filing and first-in-human

• IND submission to the FDA, with a 30-day safety review before dosing may begin. There is no user fee for an IND — the cost is the two years of package behind it.
• UK route: a Clinical Trial Authorisation from the MHRA, reviewed jointly with a Research Ethics Committee under the combined review process.
• Site activation, first patient dosed, and the moment the plan's financing assumptions meet reality.

Write the plan so a reader can find, in under a minute, what the next gate is and what it costs. Everything else in the document is supporting evidence for that one claim. Our bespoke business plan service builds this ladder as the document's organising structure rather than bolting a forecast onto a science summary.

What It Costs to Stand One Up

Ask what it costs to start a biopharmaceutical company and you will get answers ranging from "a laptop and a licence agreement" to "a billion dollars." Both are true, because the question is badly posed. The useful question is: what does it cost to get this specific asset from where it is now to the next point where someone else will pay more for it than you paid to get there?

For a virtual company taking a single biologic from a university licence to a filed IND, the realistic band is $750K to $4.2M (£590K to £3.3M). That number excludes the clinical programme itself. It is the cost of becoming fileable. Founders routinely quote the low end of that band in a seed deck and then discover the GMP batch alone consumes it.

The line item nobody budgets: the BLA fee

Years later, when the science has worked, there is a fixed cost sitting at the end of the road that has nothing to do with your biology. For fiscal year 2026, the FDA application fee for a Biologics License Application requiring clinical data is $4,682,003; an application not requiring clinical data is assessed at half that, $2,341,002. Those rates run from 1 October 2025 through 30 September 2026 (Federal Register, Prescription Drug User Fee Rates for FY 2026).

It is not the largest number in your model, but it is the most instructive one, because it is knowable today and almost no first-time plan contains it. Under PDUFA VII, 80% of user-fee revenue now comes from annual programme fees rather than application fees, and a sponsor is not assessed more than five programme fees per fiscal year for products under a single approved BLA (FDA, Prescription Drug User Fee Amendments). If you are modelling a biosimilar instead, you are on the 351(k) pathway with its own BsUFA fee schedule — a different set of numbers that founders regularly copy across by mistake.

Funding routes that actually apply

Most business plan advice points founders at SBA 7(a) loans and UK Start Up Loans. For a biopharmaceutical company both are close to irrelevant, and saying so in your plan is a credibility signal. A £25,000 Start Up Loan does not move a programme that needs seven figures of GLP tox. Debt against a pre-revenue asset with a decade to market is not a product any high-street lender sells. The realistic ladder looks like this:

• Non-dilutive grants first. NIH SBIR hard caps sit at $314,363 for Phase I and $2,095,748 for Phase II in total costs, with waivers available on certain topics for larger awards (NIAID, Know Your Actual Budget Cap). A Phase I into Phase II sequence funds roughly $2.41M of IND-enabling work at zero dilution — somewhere between 28% and 48% of the package above. Founders who sell equity to fund work a grant would have paid for are making an expensive choice quietly.
• Seed and Series A. Roughly $38B of venture capital was deployed into biotech in 2025 (BioBucks, 2025 Biotech Venture Funding), with median Series A rounds back in the $50–80M band across 2025–2026 (Vision Life Sciences, Biotech Venture Capital Guide). Note the distribution is barbelled: megarounds pull the median up while early formation stays hard to fund. A plan that assumes it is average is planning for a round that few companies get.
• Strategic and corporate venture. Pharma corporate venture arms buy optionality on assets they may later licence. The money arrives with an implicit thesis about who eventually owns the drug.
• Out-licensing an earlier asset to fund the lead. Covered in the revenue section below.
• UK-specific: Innovate UK grants, R&D tax credits, and SEIS/EIS for the earliest rounds. SEIS in particular is the only place a £250K cheque meaningfully changes a UK biotech's trajectory, and structuring for it is a plan-level decision, not an accounting afterthought.

If you want the funding narrative written around your actual ladder rather than a generic template, our market research and content service builds it from your programme data.

Choosing a CDMO: The Decision That Sets Your Burn

Build or buy is the largest structural choice in a biopharmaceutical business plan, and most first drafts get it backwards. Founders write a facility into the plan because a facility feels like a company. Investors read a facility and see fixed cost attached to an asset that has not yet earned the right to exist.

The default answer for a company with one clinical asset is a contract development and manufacturing organisation. You rent capacity, expertise, and a regulatory track record you could not build in five years. You pay a premium per gram and you keep the option to walk away. The plan should state the choice explicitly and defend it — silence here reads as a decision not yet made.

The partners you will actually be quoting

The biologics CDMO market is concentrated. Naming your shortlist, with the reason for each, does more for a plan's credibility than a page of manufacturing theory:

• Lonza (Switzerland) — the largest pure-play CDMO by mammalian capacity, with roughly $7.5B in revenue. Reinforced by the 2024 acquisition of the Vacaville large-scale site and continued build-out at Visp. The default incumbent for a mAb, and priced accordingly.
• Samsung Biologics (South Korea) — approximately $3.2B revenue and around 604,000L of capacity across four plants at Bio Campus I in Songdo, with a fifth Incheon plant of 600,000L+ targeted operational in H2 2026. Now ranked among the global top three. Strong on large-scale commercial supply; less natural for a tiny first clinical batch.
• Catalent (US) — acquired by Novo Holdings for $16.5B in December 2024, a transaction worth understanding before you sign, because ownership changes shift capacity priorities.
• WuXi Biologics (China) — roughly $2.8B revenue, historically the fastest route from gene to IND. Geopolitical exposure to US biosecurity legislation is now a live diligence question your investors will ask, so address it in the plan rather than waiting to be asked.
• Thermo Fisher Scientific — around $3.5B in pharma services revenue, with the advantage of bundling analytical and clinical supply alongside manufacture.
• Fujifilm Diosynth Biotechnologies — a major biologics CDMO with a strong reputation in process development for sponsors who want engineering depth early.

Revenue and capacity figures: Mordor Intelligence, Biologics CDMO companies; Korea Biomedical Review, 2025.

If you insist on building

Some plans genuinely need in-house capacity — a platform company selling manufacture as the product, or a cell therapy where the process is the asset. If that is you, the equipment line is knowable rather than hand-waved. Single-use systems dominate at clinical scale, and published catalogue anchors put a Thermo Fisher HyPerforma 50L single-use bioreactor with controller at roughly $45,000 per system, a Cytiva Xcellerex XDR-500 with five bags at roughly $120,000 per system, and 500–2,000L production-scale single-use systems in a $150,000–$350,000 corridor, with consumable bags at $800–$5,000 each (IndexBox supplier-catalogue analysis). Sartorius, Cytiva and Merck Millipore round out the vendor set alongside Thermo Fisher.

Those are list prices, not transaction prices — distributor discounts and volume agreements move them. But a plan that quotes a real anchor and says "list, before negotiation" is trusted more than a plan that quotes a suspiciously round number. And note what the numbers imply: the hardware is rarely the constraint. The facility, the qualification, the QA headcount, and the years of inspection history are the constraint. That is exactly what a CDMO sells you.

What to put in the plan

• Named shortlist with the reason each is on it, and which one you have actually spoken to.
• Indicative quote or a defensible estimate for cell-line development, process development, and the first GMP batch — as separate lines, not one blended number.
• Slot availability. Capacity is booked months out; a plan whose timeline assumes an immediate slot is a plan whose timeline is wrong.
• Comparability strategy if you intend to change scale or site later, because regulators will ask and it is cheaper to answer now.
• Tech-transfer risk and what it does to the critical path if the first run fails — because sometimes it does.

FDA, MHRA and the EMA Centralised Procedure

Biologics are regulated differently from small-molecule drugs, and the difference is not cosmetic. In the US you are filing under Section 351 of the Public Health Service Act, not a conventional new drug application. Post-Brexit, the UK is a standalone jurisdiction with its own filing. In the EU, the centralised procedure is not one option among several — for biotechnology-derived medicines it is mandatory. Founders who assume a single global filing get a rude introduction to their own budget.

United States

• Investigational New Drug (IND) application. No user fee. A 30-day FDA safety review before first dosing. The cost is the two years of IND-enabling work behind the submission.
• Pre-IND meeting. Free, structured, and consistently the highest-return regulatory activity available to a small sponsor. Ask the questions you are afraid of.
• Biologics License Application (BLA), Section 351 of the PHS Act. $4,682,003 in FY2026 with clinical data, $2,341,002 without. Standard review is ten months from filing; six under priority review. Reviewed by CBER or CDER depending on product class — know which one owns your molecule before you write the plan, because their expectations differ.
• PDUFA VII programme fees. Annual, capped at five per approved BLA per fiscal year.
• cGMP compliance under 21 CFR Parts 210/211 and the 600-series. A pre-licence inspection precedes approval, and it inspects your CDMO as well as you.
• Biosimilar route (351(k)) if you are entering against an existing biologic, under the separate BsUFA fee structure.

United Kingdom

• Clinical Trial Authorisation (CTA) from the MHRA, reviewed jointly with a Research Ethics Committee under the combined review process introduced by the UK clinical trials regulations reform (GOV.UK, Apply for clinical trial authorisation). MHRA confirms there is no annual clinical trials fee — the cost is per application.
• MIA(IMP) — Manufacturer's/Importer's Authorisation for Investigational Medicinal Products. Required before you manufacture or import trial material into the UK. It brings a named Qualified Person and a real quality system with it.
• MHRA Phase I Accreditation Scheme. Voluntary, but relevant if your first-in-human work runs at a UK unit.
• UK Marketing Authorisation. A separate filing from the EU, post-Brexit. Use the MHRA Application Fees Calculator for a current figure rather than quoting a stale number — around 90% of MHRA statutory fees rose between 8.85% and 22% from 1 April 2025, with the steepest increases on scientific advice meetings and inspections (GOV.UK, Current MHRA fees).
• MHRA scientific advice. The UK analogue of a pre-IND meeting, and now one of the fee lines that rose most.

European Union

• Centralised procedure, mandatory for biotechnology-derived medicines. One application, one EMA assessment, one authorisation valid across the EU. Advanced therapy medicinal products — cell and gene therapies — follow the same route.
• Fee regime. Since 1 January 2025, EMA fees have been governed by Regulation (EU) 2024/568, the "new fee regulation," with fees and charges listed per procedure in its annexes (EMA, Fees payable to the European Medicines Agency).
• Annual fee per authorisation. EMA charges an annual fee for each marketing authorisation granted under the centralised procedure — a recurring line most plans omit entirely.

Three jurisdictions, three filings, three fee schedules, one molecule. The plan does not need to solve all of it. It needs to show you know which one you are filing first, why, and what it costs. If your programme is diagnostics-led rather than therapeutics-led the timelines compress considerably — two to five years to commercialisation rather than seven to ten — which is a different plan, and often a different company.

Money Before a Product Exists

Here is the section that separates a biopharmaceutical plan from every other plan on this site. You are asking someone to fund a company that will spend for years and sell nothing. So the revenue section cannot be a hockey stick with a launch date on it. It has to answer a harder question: what are the events that convert science into cash, and when do they happen?

The four ways cash arrives

• Out-licensing an asset. Reach scientific proof-of-concept, then licence the asset to a partner who develops and commercialises it. Structure is an upfront payment, development and regulatory milestones, and royalties on future sales — commonly reaching double digits. Many small biotechs survive not by bringing drugs to market but by developing assets into early or mid-stage trials and selling them on.
• Platform and service licensing. If your technology can contribute to someone else's R&D, licensing the platform plus related services generates income sooner and at lower risk than carrying your own asset to approval. It also creates a validation signal investors read as third-party diligence.
• Non-dilutive grant income. SBIR, Innovate UK, disease foundations, and translational funds. Not revenue in the accounting sense, but it extends runway without touching the cap table, which is what the money is for.
• Acquisition. The outcome much of the industry is actually built around — a takeover by a company with commercialisation infrastructure. Your plan should be legible to an acquirer's corporate development team, not only to a VC.

Margins, honestly

An approved biologic at commercial scale is one of the highest-margin products in any industry: gross margins of 80–90% are routine, and manufacturing COGS on a well-optimised monoclonal antibody falls to a small single-digit percentage of net price. That is the prize, and it is why the capital keeps coming despite the failure rate.

Company-level net margin, though, is deeply negative until an asset is approved or out-licensed. Both facts belong in the plan, adjacent to each other. A plan that shows only the 85% gross margin is selling. A plan that shows the 85% alongside eight years of negative net is explaining — and explaining is what gets funded.

Worked example: what one Phase I actually costs

Take a monoclonal antibody entering a 24-month first-in-human study with 42 patients. US Phase I trials carry an average per-patient cost of $136,783, which puts direct clinical cost at roughly $5.75M. Add a $1.9M GMP clinical batch, $480K of CRO oversight, and $620K of regulatory and CMC support, and the programme line reaches approximately $8.75M.

Now compare that against the headline range you will find quoted everywhere: US Phase I trials cost $1.4M–$6.6M, with an average around $4M across therapeutic areas; Phase II runs $7.0M–$19.6M (average ~$13M); Phase III runs $11.5M–$52.9M (average ~$20M) (ASPE, Examination of Clinical Trial Costs and Barriers for Drug Development). Our worked antibody sits above the top of the Phase I band. That is not an error in the model — it is the biologics premium. Those published ranges are dominated by small molecules, where nobody is paying $1.9M for drug substance.

Against a $50–80M median Series A, that single Phase I consumes 11–18% of the round. Per-patient costs are also moving: between 2013 and 2023 the average cost per patient in a Phase III trial rose by nearly 50%, with oncology trials frequently exceeding $100,000 per patient. Build your model with cost inflation in it, because your programme will run through years of it.

Per-patient and phase-cost figures: ASPE (US Dept of Health & Human Services); Abacum, Clinical Trial Costing. Composition of the worked example is an Avvale planning model.

The forecast investors actually want

Not a P&L. A financing plan:

• Cash by quarter against named milestones, with the month the money runs out stated plainly.
• Risk-adjusted NPV on the lead asset, with probability of technical and regulatory success applied by phase and the source of those probabilities named.
• Comparable transactions: what similar assets licensed for, at which stage, on what structure.
• Dilution path through to exit, so founders and investors are looking at the same cap table.
• The decision point: at end-of-Phase-I, do you licence or raise a Series B? Answer it in the plan. Companies that leave it open discover it gets answered for them.

The Biopharmaceutical Market in 2026

The global biologics market was valued at $626.2 billion in 2025 (Grand View Research, Biologics Market). Estimates for the closely-related biopharmaceutical market vary widely by definition and methodology — published 2025 figures range from roughly $474B to $666B depending on whether the analyst counts vaccines, blood products, and cell therapies. That spread is not a flaw to hide. Quote your source, state its scope, and note the range. A plan that presents one number as fact when six exist is a plan whose diligence has already failed.

What the concentration means for your plan

Monoclonal antibodies took 66.3% of the biologics market in 2025, and North America took 44.4% of it. The North America biopharmaceutical market alone generated $247.4 billion in revenue in 2024 (Grand View Research, North America biopharmaceutical outlook).

Two consequences follow, and both belong in the strategy section rather than the market section. First, if you are developing a mAb you are entering the most crowded, best-understood, most manufacturing-commoditised part of the industry — cheap to develop relative to novel formats, and hard to differentiate. Your plan needs a reason the asset wins that is not "it's an antibody." Second, if you are not developing a mAb — a bispecific, an ATMP, an oligonucleotide — you are in the 33.7%, where CMC risk is higher, CDMO options are fewer, and the plan must spend more of its length on manufacturability. Neither is better. They are different plans, and a template that treats them identically has not helped you.

The UK position

The UK biopharmaceutical subsector is substantial and specific. Office for Life Sciences official statistics record 2,960 companies in the biopharmaceutical subsector generating £98.9 billion in turnover — 67% of the entire UK life sciences industry total — and employing 163,600 people, 45% of all life sciences employment. The wider industry comprises 6,170 businesses across 7,320 companies, employing 359,600 people on £146.9 billion of turnover (Office for Life Sciences, Bioscience and health technology sector statistics 2023 to 2024).

Read those two numbers together: biopharma is 40% of the companies but 67% of the turnover. It is a subsector of relatively few, relatively large revenue generators — which is exactly why the UK ecosystem is organised around clusters and out-licensing rather than around thousands of independent commercial-stage firms. If your plan is UK-based, the Golden Triangle geography, the proximity to a cluster, and the NHS trial-access argument are real assets. Use them, with the actual figures, rather than asserting that the UK is "a leading life sciences hub."

For adjacent scopes, see our biotech business plan template if your company is platform-led rather than asset-led, or the clinical trials business plan template if you are building the trial infrastructure rather than the drug. A broader starting point sits on our free business plan template hub.

Questions Founders Ask First

These come up in almost every first call. They are worth answering before you start writing, because each one changes the shape of the document.

What is the difference between a biopharmaceutical and a pharmaceutical company?

Manufacturing origin. Biopharmaceutical companies make medicines from living systems — mammalian cells, bacteria, yeast. Traditional pharmaceutical companies synthesise drugs from chemical and plant-based compounds. The consequence is commercial, not academic: biologics are large, structurally complex, sensitive to process, expensive to make, and difficult to copy exactly, which is why the generic equivalent is called a biosimilar rather than a generic. Biologics dominate oncology, autoimmune disease, and rare genetic disorders, where small molecules underperform. They also take longer to produce and cost more per gram at every scale. Your plan inherits all of that.

How do biopharmaceutical companies make money before FDA approval?

Four routes, covered in detail above: out-licensing an asset after proof-of-concept for an upfront plus milestones plus royalties; licensing a platform and selling related services to better-funded sponsors; non-dilutive grant income; and acquisition. The common thread is that value is realised at scientific and regulatory inflection points, not at a launch date. Once technology is mature enough to reliably contribute to someone else's R&D, licensing it out generates income faster and at lower financial risk than carrying an asset alone.

How long does it take to become profitable?

For a therapeutics company, the honest answer is that most never do — they are acquired or out-licensed first, and that is a success, not a failure. Discovery to market runs seven to ten years for therapeutics. Diagnostics reach commercialisation in two to five. If your plan needs a profitability date to satisfy a grant form, anchor it to a licensing event rather than a product launch and say so explicitly.

Do I need my own manufacturing facility?

Almost certainly not, and putting one in the plan before you have an asset worth manufacturing works against you. A CDMO gives you capacity, expertise, and inspection history you cannot build in the time available. Build only when manufacture is the product.

How much does it cost to start one?

To reach a filed IND with a single biologic using contract partners: $750K–$4.2M (£590K–£3.3M), of which up to $2.41M can be non-dilutive via an NIH SBIR Phase I into Phase II sequence. The clinical programme is separate and larger. The BLA at the far end carries a $4,682,003 FY2026 fee on its own.

What licence do I need to sell a biologic?

In the US, an approved BLA under Section 351 of the Public Health Service Act, preceded by a pre-licence inspection. In the UK, an MHRA marketing authorisation — a standalone filing since Brexit. In the EU, an authorisation via the mandatory centralised procedure. Trial-stage activity needs an IND (US) or a CTA plus MIA(IMP) (UK) before that.

Five mistakes that cost founders the round

• The year-five revenue line. Presenting a conventional revenue forecast for a company that will have no product revenue in year five. It tells the reader you do not understand your own asset, in the first exhibit they open.
• Budgeting the trial, forgetting the drug. GMP material for a first-in-human study routinely costs more than the clinic that consumes it.
• Treating the BLA as paperwork. It is a ~$4.68M fixed cost plus an inspection of you and your CDMO.
• Assuming UK and EU are one filing. They have not been since Brexit. Two filings, two fee schedules, two timelines.
• Selling equity to do grant-funded work. $2.41M of SBIR capacity left on the table is dilution you chose without noticing.

Sample Business Plan Preview

Preview the structure and financial outputs a buyer receives. These mockups are generated from the same phase-gated assumptions used throughout this page.

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your business at a glance, written to hook investors in 60 seconds
• Company Overview — Legal structure, ownership, location, and founding story
• Industry Analysis — Market size, growth trends, and the regulatory environment
• Customer Analysis — Target demographics, pain points, and spending patterns
• Competitor Analysis — Competitive mapping and your differentiation strategy
• Marketing Plan — Channels, messaging, and customer acquisition strategy
• Operations Plan — Day-to-day workflows, staffing structure, and key milestones
• Management Team — Founder bios, advisory board, and key hires planned

For a biopharmaceutical plan, four of those sections carry a different load than they would elsewhere, and it is worth knowing where to push:

• Industry Analysis becomes the regulatory pathway. Which agency, which filing, which fee, which timeline.
• Operations Plan becomes CMC and the CDMO relationship. Name the partner, name the batch, name the slot.
• Competitor Analysis becomes a competitive-asset map: what else is in development for your indication, at what phase, owned by whom. Not "other companies in biotech."
• Management Team carries unusual weight, because at pre-clinical stage the team is most of what an investor can actually diligence. A CMC-experienced co-founder changes the risk profile of the whole document.

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements. For pre-revenue biopharmaceutical companies we restructure that model around phase-gated spend and risk-adjusted asset value rather than a product P&L.

Frequently Asked Questions

Useful Links & Resources

These links were preserved from the live page so important references and partner links are not lost during the page refresh.

• Facebook
• Instagram
• LinkedIn
• YouTube